Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies

por Miljkovic, Milos D., Dubois, Sigrid P., Müller, Jürgen R., Bryant, Bonita, Ma, Elaine, Conlon, Kevin C., Waldmann, Thomas A.
Publicado 2022

A very long-acting IL-15: implications for the immunotherapy of cancer

por Hangasky, John A, Chen, Wei, Dubois, Sigrid P, Daenthanasanmak, Anusara, Müller, Jürgen R, Reid, Ralph, Waldmann, Thomas A, Santi, Daniel V
Publicado 2022

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

por Dubois, Sigrid P, Miljkovic, Milos D, Fleisher, Thomas A, Pittaluga, Stefania, Hsu-Albert, Jennifer, Bryant, Bonita R, Petrus, Michael N, Perera, Liyanage P, Müller, Jürgen R, Shih, Joanna H, Waldmann, Thomas A, Conlon, Kevin C
Publicado 2021